Abstract
Progress has been made towards the development of agents targeting tyrosine kinase receptors and other molecules involved in signalling pathways important for cell proliferation, motility, and apoptosis. Inhibitor molecules designed to be highly specific with the aim of decreasing toxicity have proven to be generally well tolerated. However, the efficacy of targeted agents may be impacted by cross-talk between pathways and downregulation of negative feed-back loops. That is the case of the IGF-IR/PI3K/Akt/mTOR pathway. This issue raises the question of how these targeted agents could be combined to prevent or delay resistance without significantly increasing toxicity. Several mTOR inhibitors have been approved for cancer therapy, and late-stage clinical trials of IGF-IR inhibitors are underway. The outcome of ongoing clinical studies of IGF-IR, PI3K, Akt and mTOR inhibitors as well as further testing of the combination of these agents will be key for the development of therapeutic options in a wide range of oncology indications.
Reviews on Recent Clinical Trials
Title: Development of Inhibitors of the IGF-IR/PI3K/Akt/mTOR Pathway
Volume: 5 Issue: 3
Author(s): Mary L. Hixon, Luisa Paccagnella, Robert Millham, Raul Perez-Olle and Antonio Gualberto
Affiliation:
Keywords: IGF-IR, PI3K, Akt, mTOR
Abstract: Progress has been made towards the development of agents targeting tyrosine kinase receptors and other molecules involved in signalling pathways important for cell proliferation, motility, and apoptosis. Inhibitor molecules designed to be highly specific with the aim of decreasing toxicity have proven to be generally well tolerated. However, the efficacy of targeted agents may be impacted by cross-talk between pathways and downregulation of negative feed-back loops. That is the case of the IGF-IR/PI3K/Akt/mTOR pathway. This issue raises the question of how these targeted agents could be combined to prevent or delay resistance without significantly increasing toxicity. Several mTOR inhibitors have been approved for cancer therapy, and late-stage clinical trials of IGF-IR inhibitors are underway. The outcome of ongoing clinical studies of IGF-IR, PI3K, Akt and mTOR inhibitors as well as further testing of the combination of these agents will be key for the development of therapeutic options in a wide range of oncology indications.
Export Options
About this article
Cite this article as:
L. Hixon Mary, Paccagnella Luisa, Millham Robert, Perez-Olle Raul and Gualberto Antonio, Development of Inhibitors of the IGF-IR/PI3K/Akt/mTOR Pathway, Reviews on Recent Clinical Trials 2010; 5 (3) . https://dx.doi.org/10.2174/157488710792007329
DOI https://dx.doi.org/10.2174/157488710792007329 |
Print ISSN 1574-8871 |
Publisher Name Bentham Science Publisher |
Online ISSN 1876-1038 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
The Important Roles of miR-205 in Normal Physiology, Cancers and as a Potential Therapeutic Target
Current Cancer Drug Targets Targeting Cell Death and Survival Receptors in Hepatocellular Carcinoma
Anti-Cancer Agents in Medicinal Chemistry Emerging Role of Cetuximab in the Treatment of Colorectal Cancer
Recent Patents on Anti-Cancer Drug Discovery CXCL8 as a Potential Therapeutic Target for HIV-Associated Neurocognitive Disorders
Current Drug Targets Synthesis and Cytotoxic Activity of New β-Carboline Derivatives
Mini-Reviews in Medicinal Chemistry Prognostic Markers in Small Cell Lung Cancer
Current Cancer Therapy Reviews Liposomal Muramyl Tripeptide Phosphatidylethanolamine: Targeting and Activating Macrophages for Adjuvant Treatment of Osteosarcoma
Current Cancer Drug Targets Nanosized Modification Strategies for Improving the Antitumor Efficacy of MEK Inhibitors
Current Drug Targets A Perspective on Stem Cells as Biological Systems that Produce Differentiated Osteoblasts and Odontoblasts
Current Stem Cell Research & Therapy Patenting Penicillium Strains
Recent Patents on Biotechnology Meta-analysis Reveals No Association of DNMT3B -149 C>T Gene Polymorphism With Overall Cancer Risk
Current Genomics Development, Characterization and Anticancer Evaluation of Silver Nanoparticles from Dalbergia sissoo Leaf Extracts
Current Cancer Therapy Reviews Kinase Inhibitor Conjugates
Current Pharmaceutical Design Cannabinoids: Do they have a Role in Cancer Therapy?
Letters in Drug Design & Discovery Editorial [Low Grade Inflammation as a Common Pathogenetic Denominator in Age-Related Diseases: Novel Drug Targets for Anti-Ageing Strategies and Successful Ageing Achievement. PART I. (Executive Editors: Calogero Caruso Thea Magrone and Emilio Jirilllo)]
Current Pharmaceutical Design Computer Techniques for Drug Development from Thai Traditional Medicine
Current Pharmaceutical Design Aspirin Use on Incidence and Mortality of Gastrointestinal Cancers: Current State of Epidemiological Evidence
Current Pharmaceutical Design Meet Our Associate Editor
Current Protein & Peptide Science Nano-Tetrandrine Efficiently Inhibits the Proliferation and Induces the Apoptosis of Hep2 Cells through a Mitochondrial Signaling Pathway
Current Signal Transduction Therapy Mitochondrial Dysfunction and Targeted Drugs: A Focus on Diabetes
Current Pharmaceutical Design